Passage BIO, Inc. (PASG): Cash & Equivalents
$46.30M
As of 2025-12-31
$24.16M
As of 2026-06-30
+10.2%
3-year compound annual growth
-19.3%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $46.30M | +23.2% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $37.57M | +73.1% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $21.71M | -37.3% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $34.60M | -73.2% | 2024-03-04, Balance as of period end |
| 2021-12-31 | $128.97M | -4.5% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $135.00M | -15.0% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $158.87M | n/a | 2021-03-03, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Passage BIO, Inc. (PASG) | 2025-12-31 | $46.30M | +23.2% |
| Elutia Inc. (ELUT) | 2025-12-31 | $36.35M | +174.6% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $17.47M | -66.1% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $20.95M | -50.0% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $36.79M | +38.1% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $16.42M | -66.0% |
| Armata Pharmaceuticals, Inc. (ARMP) | 2025-12-31 | $8.69M | -6.5% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $66.05M | +36.0% |
| Cognition Therapeutics Inc (CGTX) | 2025-12-31 | $36.81M | +47.2% |
Compare PASG, ELUT, CRDF, SGMOQ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗